Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply

Inmaculada Hernandez^{1

2}, Vinay Prasad^{3

4

5}, Walid F Gellad^{2

6}

Affiliations

¹ Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
² Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania.
³ Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland.
⁴ Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland.
⁵ Center for Health Care Ethics, Oregon Health & Science University, Portland.
⁶ Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

Comment

Inmaculada Hernandez et al. JAMA Oncol. 2018.

. 2018 Dec 1;4(12):1785-1786.

doi: 10.1001/jamaoncol.2018.4657.

Inmaculada Hernandez^{1

2}, Vinay Prasad^{3

4

5}, Walid F Gellad^{2

6}

¹ Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
² Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania.
³ Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland.
⁴ Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland.
⁵ Center for Health Care Ethics, Oregon Health & Science University, Portland.
⁶ Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

No abstract available

Comment on

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.
Hernandez I, Prasad V, Gellad WF. Hernandez I, et al. JAMA Oncol. 2018 Jul 1;4(7):994-996. doi: 10.1001/jamaoncol.2018.0977. JAMA Oncol. 2018. PMID: 29710129 Free PMC article.
Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy.
Whittington MD, Ollendorf DA, Campbell JD. Whittington MD, et al. JAMA Oncol. 2018 Dec 1;4(12):1784-1785. doi: 10.1001/jamaoncol.2018.4625. JAMA Oncol. 2018. PMID: 30325984 No abstract available.